Efferon therapy

30/04/2026

Hemoadsorption & Endothelium: The Next Breakthrough?

We can remove biomarkers, but does it actually improve patient outcomes?

Discover the hypothesis linking hemoadsorption to endothelial protection, vascular tone, and organ function. This could shape the next generation of ICU research.

🔔 Follow for more high-impact medical insights!

28/04/2026

Biomarkers or Clinical Signs? ICU Expert Explains

In critical care, timing is everything. So how do doctors decide when to start Efferon hemoadsorption therapy?

In this short, an ICU expert professor Zsolt Molnar explains why clinical condition and hemodynamic instability matter more than biomarkers alone, and when it's time to act.

👉 Watch till the end and subscribe for more real ICU insights and medical education!

27/04/2026

Efferon NEO - the world's first multimodal device designed specifically for and neonatal patients.

Watch more in the video!

Sepsis Alliance Deutschland Erkennt Sepsis The UK Sepsis Trust Sepsis Stiftung Sepsis Canada Sepsis Australia World Federation of Pediatric Intensive and Critical Care Societies European Society of Paediatric and Neonatal Intensive Care (ESPNIC)

2 likes. "First Hemoadsorption Device for Newborns & Children | A New Era in Pediatric Critical Care"

27/04/2026

From Armenia to Australia: Efferon grabs attention worldwide.

This week, at the first neurocritical care meeting in Armenia, was in the spotlight. The discussion went beyond classical applications of . It is encouraging to see how a growing medical community is actively engaging with advanced therapies, with a clear focus on improving patient outcomes and bringing innovation into daily ICU practice.

At the New Zealand Regional Scientific Meeting 2026, clinicians from leading ICUs showed strong interest in how hemoadsorption can be used in real clinical settings with diverse patient populations.

Kudos to our partners, this progress wouldn’t be possible without your commitment. Efferon hemoadsorption is becoming part of ICUs around the world, and we can't wait to see what's next!

23/04/2026

3 Clinical Effects in 24 Hours: ICU Doctor on Efferon LPS in sepsis
What do clinicians notice first when using Efferon hemoadsorption in sepsis patients? In this clip, a physician shares direct ICU experience: hemodynamic stabilization comes first. This is followed by a drop in inflammatory biomarkers, driven both by direct sorption and by the overall resolution of the inflammatory response. Improved oxygenation has also been observed in patients with severe complications.

22/04/2026

CE MDR Certified

We are proud to announce that Efferon NEO, our new pediatric multimodal hemoadsorption device, has received CE certification under the EU Medical Device Regulation (MDR). This certification confirms that Efferon Neo meets the stringent European requirements for safety, quality, and performance, and enables its use in clinical practice.

Efferon NEO is the world’s first device specifically approved for neonatal and pediatric patients with sepsis and septic shock. It is tailored to children’s lower circulating blood volume and combines selective LPS removal with broad-spectrum adsorption of cytokines, myoglobin, and other toxic substances in a single device.

Because children deserve therapies built for them 🧡
Sepsis Alliance Deutschland Erkennt Sepsis Intensive Care Society

21/04/2026

It's 2026 by Sepsis Alliance. We're joining the conversation to raise awareness of it: every year, around 20 million children develop . More than 3 million of them die. We at think this can change.

We recently hosted our first webinar for the Australian pediatric critical care community, part of our broader effort to bring to clinicians around the world. Dr. Mikhail Rusak (head of the ICU at St. Petersburg State Children's Multidisciplinary Clinical Center, 20+ years in pediatric and neonatal critical care) and our co-founder Ivan Bessonov walked through the clinical and engineering sides of the story.

The session brought together clinicians from Children's Health Queensland, Fiona Stanley Hospital, Perth Children's Hospital and Health Service, and Sydney Children's Hospital. This is the first in a series of country-focused webinars we're planning. Next up: more countries, more conversations with the people who treat critically ill children every day.

The clinical data from the LASSO NEO clinical trial is encouraging: children treated with Efferon NEO alongside standard therapy showed faster shock resolution, less organ dysfunction, reduced need for vasopressors and mechanical ventilation. These results are supported by meaningful reductions in inflammatory markers, cytokines, and endotoxin. Efferon NEO is our answer to what pediatric intensivists have been asking for: a blood purification option designed specifically for children.

Thank you to everyone who joined us and to our speakers. We also thank Sepsis Alliance for raising awareness about pediatric sepsis. It's moving the field forward, and we’re grateful to be part of it.

20/04/2026

Hemoadsorption in Septic Shock: The #1 Trigger ICU Doctors Watch For

When should clinicians start hemoadsorption in the ICU? In this video, an intensive care specialist professor Zsolt Molnar (Semmelweis University, Hungary) breaks down the clinical decision-making process: why standard therapy response matters, and why hemodynamic instability is the critical turning point that drives the decision to begin hemoadsorption.

17/04/2026

Professor Zsolt Molnar (Semmelweis University, Hungary) shares his perspective on when to initiate in critically ill patients, emphasizing that the decision is driven primarily by clinical picture rather than laboratory markers.

He highlights persistent hemodynamic instability despite standard therapy as the key trigger for treatment, noting that therapy is often associated with improved hemodynamics, reduced vasopressor demand.

He also reflects on the potential role of endothelial protection and the broader impact on ICU course, including shorter duration of organ support.

As one of the pioneers in the field of hemoadsorption, his perspective offers valuable context for both current practice and future directions. Our sincere thanks to Professor Zsolt Molnar for taking the time to share his thoughts.

When is the right moment to initiate hemoadsorption in critically ill patients?Professor Zsolt Molnar (Semmelweis University, Hungary), one of the pioneers o...

17/04/2026

Efferon at the Extracorporeal Organ Support conference this May in Zagreb!

Visit MEDICON and BERTOSSI booth to learn more about Efferon’s next-generation extracorporeal blood adsorbers for hashtag and septic shock, designed and manufactured in the European Union. Our partners will be on site to share expertise and discuss how Efferon technology is being implemented across the region.

We are also proud to highlight a lecture by Ivan Bessonov, CTO and cofounder of Efferon. His talk will focus on a next-generation multimodal hemoadsorption device, the first in the world registered for hashtag use, marking an important step forward in blood purification therapy.

We look forward to insightful discussions, new connections, and meeting colleagues face-to-face in Zagreb.

16/04/2026

We’re excited to support the upcoming Hackathon in Aachen, organized by BEST Aachen

BEST Aachen in collaboration with SchubKI GmbH!

On May 7-8, participants will work on real-world challenges in the medical field using data analysis and AI, in collaboration with industry partners. The event brings together students and companies to develop practical solutions and exchange ideas. Selected participants may also receive financial support in the form of a grant!

📍 Aachen, Germany
📆 May 7-8, 2026

Applications are open, and places are limited.
More information:

14/04/2026

At Efferon, we are working on a new solution. is a multimodal pediatric device designed for the smallest and most vulnerable patients in response to strong and growing demand from pediatricians.
A next-generation multimodal hemoadsorption device. The first of its kind in the world.
💥 Coming soon!

Dr. Gabriella Bottari, pediatric intensivist, shares her perspective on the role of hemoadsorption therapy in critically ill children and the challenges of t...